Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics reported yesterday a 32 percent rise in third quarter revenues, in part due to an increase in test and collection volume for its thyroid cancer diagnostics.

For the three-month period ended Sept. 30, Interpace's revenues climbed to $3.3 million from $2.5 million the year before, due in part to higher test and collection volume for the company's ThyraMir and ThyraGenX thyroid cancer assays. Also driving revenues was an increase in the amounts collected based on Medicare coverage for ThyraMir.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.